Technical Analysis for IMMU - Immunomedics, Inc.

Grade Last Price % Change Price Change
grade D 13.34 -26.26% -4.75
IMMU closed up 1.46 percent on Thursday, January 17, 2019, on 1.42 times normal volume. It ran into resistance at its 50 day moving average. Note that the stock is in overbought territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a pullback should not be unexpected.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Down Down
See historical IMMU trend table...

Date Alert Name Type % Chg
Jan 17 50 DMA Resistance Bearish -26.26%
Jan 17 Non-ADX 1,2,3,4 Bearish Bearish Swing Setup -26.26%
Jan 17 Pocket Pivot Bullish Swing Setup -26.26%
Jan 17 Weak + Overbought Other -26.26%
Jan 17 Outside Day Range Expansion -26.26%
Jan 17 Wide Bands Range Expansion -26.26%
Jan 17 Overbought Stochastic Strength -26.26%
Jan 16 50 DMA Resistance Bearish -25.18%
Jan 16 Stochastic Sell Signal Bearish -25.18%
Jan 16 Non-ADX 1,2,3,4 Bearish Bearish Swing Setup -25.18%

Older signals for IMMU ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Immunomedics, Inc., a biopharmaceutical company, focuses on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune, and other serious diseases. Its products include epratuzumab, which is in two Phase III clinical trials for the treatment of lupus; Yttrium-90 labeled clivatuzumab tetraxetan, a therapeutic product candidate that completed a Phase Ib clinical trial for the treatment of pancreatic cancer; and Veltuzumab, a humanized anti-CD20 monoclonal antibody for the treatment of non-Hodgkin lymphoma (NHL). The company's products also comprise Milatuzumab, a transmembrane protein that is highly expressed in MM and other B-cell lymphomas and leukemias, and in certain solid tumors; Yttrium-90-Labeled Epratuzumab Tetraxetan, a radiolabeled CD22 antibody product candidate for patients with NHL; Labetuzumab, a proprietary humanized antibody, which is in Phase II clinical development stage, targets the carcinoembryonic antigen, CEACAM5; and hRS7, an internalizing humanized anti-epithelial glycoprotein-1 antibody. It also manufactures and commercializes LeukoScan, a diagnostic imaging system to determine the location and extent of infection/inflammation in bone in patients with suspected osteomyelitis, including patients with diabetic foot ulcers. The company has strategic partnerships and relationships with Nycomed GmbH and UCB, S.A.; and a collaboration agreement with Algeta ASA for the development of epratuzumab. Immunomedics, Inc. was founded in 1982 and is headquartered in Morris Plains, New Jersey.
Is IMMU a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 27.33
52 Week Low 12.86
Average Volume 2,702,799
200-Day Moving Average 21.0184
50-Day Moving Average 18.2525
20-Day Moving Average 16.3175
10-Day Moving Average 17.364
Average True Range 1.2698
ADX 18.58
+DI 19.7976
-DI 22.2252
Chandelier Exit (Long, 3 ATRs ) 15.0906
Chandelier Exit (Short, 3 ATRs ) 16.6694
Upper Bollinger Band 19.1023
Lower Bollinger Band 13.5327
Percent B (%b) 0.82
BandWidth 34.13268
MACD Line -0.0256
MACD Signal Line -0.4194
MACD Histogram 0.3939
Fundamentals Value
Market Cap 2.01 Billion
Num Shares 111 Million
EPS -1.47
Price-to-Earnings (P/E) Ratio -12.31
Price-to-Sales 396.34
Price-to-Book 0.00
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 19.53
Resistance 3 (R3) 19.54 19.08 19.29
Resistance 2 (R2) 19.08 18.71 19.07 19.21
Resistance 1 (R1) 18.58 18.48 18.83 18.57 19.13
Pivot Point 18.12 18.12 18.24 18.11 18.12
Support 1 (S1) 17.62 17.75 17.87 17.61 17.05
Support 2 (S2) 17.16 17.52 17.15 16.97
Support 3 (S3) 16.66 17.16 16.89
Support 4 (S4) 16.65